Objectives:To detect the concentration of serum vascular endothelial growth factor (VEGF) in patients with pregnancy induced hypertension (PIH) as well as to explore the role of VEGF in the pathogenesis of Pffl.Method...Objectives:To detect the concentration of serum vascular endothelial growth factor (VEGF) in patients with pregnancy induced hypertension (PIH) as well as to explore the role of VEGF in the pathogenesis of Pffl.Methods: Serum VEGF concentrations in 23 healthy nonpregnant women (normal group) ,30 normal pregnant women (control group) and 37 women with PIH (PIH group) were measured by sandwich enzyme- linked immunoadsorbent assay (ELISA). Results: Serum concentrations of VEGF in control group were significantly higher (149.39 + 27.15ng/L) than those in normal group (11.98 + 3.99ng/L) ( P < 0.001) , peaking in the second trimester of pregnancy (183.84 + 49.02ng/L) and decreasing in the third trimester (118.37 + 34.29ng/L) . Serum VEGF concentrations (64.45 + 24.33ng/L) in PIH group were significantly lower than those in normal late pregnancy women of control group (118.37 + 34.29ng/L) ( P < 0.01) . There was a trend that serum VEGF concentrations in PIH group decreased with the severity of Pffl (P < 0.05) . Conclusion: The serum VEGF concentration in PIH women are significantly decreased, which suggests that VEGF may play an important role in the pathogenic mechanism of PIH.展开更多
Objective: The purpose of this article is to review the literature assessing foetal and maternal pregnancy outcomes in women with PCOS who used metformin during pregnancy. Study Design: A literature search was conduct...Objective: The purpose of this article is to review the literature assessing foetal and maternal pregnancy outcomes in women with PCOS who used metformin during pregnancy. Study Design: A literature search was conducted using MEDLINE, with analysis of 25 studies that recorded neonatal and maternal outcomes in women who used metformin during pregnancy. The outcomes assessed in this review include congenital deformities, miscarriages, preterm labour, gestational diabetes (GDM) and pregnancy induced hypertension (PIH). Results: We found that the use of metformin throughout pregnancy correlated with decreased rates of preterm labour, GDM and PIH. Conflicting evidence exists over whether metformin use during pregnancy reduced miscarriage rates. The use of metformin during pregnancy did not increase teratogenicity risks. Conclusion: The use of metformin throughout pregnancy is associated with decreased rates of preterm labour, GDM, and PIH. However, more randomised controls involving larger numbers of participants are required for more definitive results.展开更多
基金This study was supported by Medical Science Technique Foundation of Guangdong Province (970035)
文摘Objectives:To detect the concentration of serum vascular endothelial growth factor (VEGF) in patients with pregnancy induced hypertension (PIH) as well as to explore the role of VEGF in the pathogenesis of Pffl.Methods: Serum VEGF concentrations in 23 healthy nonpregnant women (normal group) ,30 normal pregnant women (control group) and 37 women with PIH (PIH group) were measured by sandwich enzyme- linked immunoadsorbent assay (ELISA). Results: Serum concentrations of VEGF in control group were significantly higher (149.39 + 27.15ng/L) than those in normal group (11.98 + 3.99ng/L) ( P < 0.001) , peaking in the second trimester of pregnancy (183.84 + 49.02ng/L) and decreasing in the third trimester (118.37 + 34.29ng/L) . Serum VEGF concentrations (64.45 + 24.33ng/L) in PIH group were significantly lower than those in normal late pregnancy women of control group (118.37 + 34.29ng/L) ( P < 0.01) . There was a trend that serum VEGF concentrations in PIH group decreased with the severity of Pffl (P < 0.05) . Conclusion: The serum VEGF concentration in PIH women are significantly decreased, which suggests that VEGF may play an important role in the pathogenic mechanism of PIH.
文摘Objective: The purpose of this article is to review the literature assessing foetal and maternal pregnancy outcomes in women with PCOS who used metformin during pregnancy. Study Design: A literature search was conducted using MEDLINE, with analysis of 25 studies that recorded neonatal and maternal outcomes in women who used metformin during pregnancy. The outcomes assessed in this review include congenital deformities, miscarriages, preterm labour, gestational diabetes (GDM) and pregnancy induced hypertension (PIH). Results: We found that the use of metformin throughout pregnancy correlated with decreased rates of preterm labour, GDM and PIH. Conflicting evidence exists over whether metformin use during pregnancy reduced miscarriage rates. The use of metformin during pregnancy did not increase teratogenicity risks. Conclusion: The use of metformin throughout pregnancy is associated with decreased rates of preterm labour, GDM, and PIH. However, more randomised controls involving larger numbers of participants are required for more definitive results.
